Prostate-Specific Antigen Increase during Dutasteride to Indicate the Need for Prostate Biopsy: Influence of Prostatic Inflammation

Abstract

Introduction

The aim of this study was to analyze the significance of an increase in total prostate-specific antigen (PSA) serum levels despite dutasteride treatment as a predictor of prostate cancer (PC) at biopsy. We focused our attention on the rate of the first PSA increase and on the influence of prostatic inflammation.

Methods

From 2011 to 2016, 365 men with a previous negative prostate biopsy and persistent elevated PSA levels received dutasteride treatment. The population was followed for a range of 12-48 months.

Results

One hundred twelve cases with a confirmed PSA increase >0.5 ng/ml over the nadir value during the follow-up were included in Group A and underwent a new prostate biopsy. In Group A, the PSA increase was associated with PC at the re-biopsy in 66% of cases. The percentage of PSA reduction after 6 months of treatment was not a significant indicator of the risk for PC. The distribution of inflammatory infiltrates significantly (p<00.01) varied from positive to negative prostate biopsies. The relative risk for PC at biopsy significantly increased according to PSA level during dutasteride.

Conclusions

Treatment with dutasteride can help to analyze PSA kinetic. A persistent prostatic inflammation is a factor able to reduce the performance of PSA kinetic during dutasteride treatment.

Keywords

Dutasteride Prostate neoplasm Prostate-specific antigen Prostatic hyperplasia Prostatitis

Get full access to this article

View all access options for this article.

References

Andriole

Bostwick

Brawley

The effect of dutasteride on the usefulness of PSA for the diagnosis of high grade and clinically relevant prostate cancer in men with a previous negative biopsy: results from the REDUCE study. J Urol 2011; 185:126-131

Marks

Andriole

Fitzpatrick

Schulman

Roehrborn

The interpretation of serum PSA in men receiving 5 alpha reductase inhibitors: a review and clinical recommendations. J Urol 2006; 176:868-874

Thompson

Chi

Ankerst

Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. J Natl Cancer Inst 2006; 98 (16): 1128-1133

Roehrborn

Andriole

Wilson

Castro

Rittmaster

Effect of dutasteride on prostate biopsy rates and the diagnosis of prostate cancer in men with lower urinary tract symptoms and enlarged prostates in the Combination of Avodart and Tamsulosin trial. Eur Urol 2011; 59 (2): 244-249

Heidenreich

Bastian

Bellmunt

Bolla

Joniau

Mason

Prostate cancer. EAU guidelines

2016;1-152

Andriole

Bostwick

Brawley

REDUCE Study Group. Effect of dutasteride on the risk of prostate cancer. N Engl J Med 2010; 362 (13): 1192-1202

Gormley

Stoner

Bruskewitz

The Finasteride Study Group. The effect of finasteride in men with benign prostatic hyperplasia. N Engl J Med 1992; 327 (17): 1185-1191

Marberger

Freedland

Andriole

Emberton

Pettaway

Montorsi

Usefulness of PSA rise as a marker of prostate cancer in men treated with dutasteride: Lessons from the REDUCE study. BJU Int 2011; 109:1162-1169

Vickers

Sjoberg

Decision analysis of dutasteride use for patients with negative prostate biopsy. Urology 2015; 85 (2): 337-341

10.

Kravchick

Lobik

Cytron

Kravchenko

Dor

Peled

Patients with persistently elevated PSA and negative results of TRUS-biopsy; does 6-month treatment with dutasteride can indicate candidates for re-biopsy. What is the best of saturation schemes:transrectal or transperineal approach? Pathol Oncol Res 2015; 21 (4): 985-989

11.

Moreira

Nickel

Gerber

Baseline prostate inflammation is associated with a reduced risk of prostate cancer in men undergoing repeat prostate biopsy: results from the REDUCE study. Cancer 2014; 120 (2): 190-196

12.

Andriole

Bostwick

Gomella

Modeling and analysis of Gleason score 810 prostate cancers in the REDUCE study. Urology 2014; 84 (2): 393-399